PROSPECTS OF PHARMACOLOGICAL APPLICATION OF NEUROPEPTIDE Y AND ITS FRAGMENTS
DOI:
https://doi.org/10.11603/mcch.2410-681X.2019.v0.i1.10015Keywords:
neuropeptide Y, biologically active peptide, stress, post-traumatic stress disorder, obesityAbstract
Introduction. The article presents an overview of the literature data on the biologically active peptide – neuropeptide Y, the system of its receptors, their role in the human body and research on the study of their therapeutic and preventive effectiveness. The study of endogenous compounds with biological activity opens the way to the creation of new safe medicines for the therapy and prevention of various pathological conditions. Neuropeptide Y is a biologically active peptide widespread in the human body, and performs various functions, such as regulation stress, anxiety, cognitive processes, nutrition behavior, etc. NPY activates 4 of its own receptors in humans, located in the brain and various internal organs, which explains its wide range of biological activity. Studies showing the therapeutic potential of neuropeptide Y and NPY receptor activating compounds for the correction of obesity, the treatment of alcohol addiction, the treatment of depression, stress, and post-traumatic stress disorder are given, its ability to influence the course of neurodegenerative diseases is shown. The development of drugs agonists and antagonists to NPY receptors. Compounds tumor target are developed. The development of drugs agonists and antagonists to NPY receptors. During development, compounds of both peptide and non-peptide nature that can activate NPY receptors are investigated. One of the ways of development is the modification of the NPY molecule at which chain reduction is carried out, using functionally important sectors, and the replacement of amino acid residues.
The aim of the study – to learn modern sources of literature on the medical use and potential benefits of neuropeptide Y drugs.
Conclusion. Based on the studied literature, it can be assumed that the study of the NPY system opens up a promising direction of targeted drug development for the correction of a number of metabolic disorders. Given the wide location of the points of application of NPY in the body, perhaps a therapeutic effect on various organs and systems.
References
Reichmann, F., & Holzer, P. (2015). Neuropeptide Y: A stressful review. Neuropeptides., 55, 99-109
Pedragosa-Badia, X., Stichel, J., & Beck-Sickinger, A.G. (2013). Neuropeptide Y receptors: how to get subtype selectivity. Frontiers in Endocrinology, 4. doi:10.3389/fendo.2013.00005
Yi, M., Li, H., Wu, Z., Yan, J., Liu, Q., Ou, C., & Chen M. (2018). A promising therapeutic target for metabolic diseases: Neuropeptide Y receptors in humans. Cell. Physiol. Biochem., 45, 88-107.
Thorsell, A., & Mathé, A.A. (2017). Neuropeptide Y in alcohol addiction and affective disorders. Frontiers in Endocrinology, 8, 178. doi:10.3389/fendo.2017.00178
Nozdrachev, A.D., & Maslyukov, P.M. (2011). Neyropeptid Y i avtonomnaya nervnaya sistema [Neuropeptide Y and the autonomic nervous system]. Zhurnal evolyutsionnoy fiziologii i biokhimii – Journal of Evolution and Biochemistry, 2, 105-112 [in Russian].
Ruscica, M., Dozio, E., & Magni, P.(2010). NPY (neuropeptide Y). Atlas Genet. Cytogenet. Oncol. Haematol., 14, 404-408.
Sundström, G. (2010). Evolution of the neuropeptide Y and opioid systems and their genomic regions. Uppsala: Acta Universitatis Upsaliensis.
Benarroch, E.E. (2009). Neuropeptide Y: its multiple effects in the CNS and potential clinical significance Neurology, 72, 1016-1020.
Eaton, K., Sallee, F.R., & Sah, R. (2007). Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top Med. Chem., 7, 1645-1659
van den Pol, A.N. (2012). Neuropeptide transmission in brain circuits. Neuron., 76, 98-115
Wu, G., Feder, A., & Wegener, G. (2011). Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin. Ther. Targets., 15, 1317-1331.
Sayed, S, Van Dam, N.T., Horn, S.R., Kautz, M.M., Parides, M., & Costi, S., et al. (2017). A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. Int. J. Neuropsychopharmacol., 21, 3-11.
Brothers, S.P., & Wahlestedt, C. (2010). Therapeutic potential of neuropeptide Y (NPY) receptor ligands EMBO Mol. Med., 2, 429-439.
Decressac, M., & Barker, R.A. (2012). Neuropeptide Y and its role in CNS disease and repair. Exp. Neurol., 238, 265-272.
Lee, D.Y., Hong, S.H., Kim, B., Lee, D.S., Yu, K., & Lee, K.S. (2018). Neuropeptide Y mitigates ER stress–induced neuronal cell death by activating the PI3K–XBP1 pathway. European Journal of Cell Biology., 97, 339-348.
Cohen, H. (2012). The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder Neuropsychopharmacology, 37, 350-363.
Zwanziger, D., Bohme, I., Lindner, D., & Beck-Sickinger, A.G. (2012). First selective agonist of the neuropeptide Y1-receptor with reduced size. J. Pept. Sci., 15, 856-866.
Walther, C., Morl, K., & Beck-Sickinger, A.G. (2011). Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J. Pept. Sci., 17, 233-246
Konstantinos, L., Karavis, M., Mastorakos, G., & Valsamakis, G. (2015). New molecular targets for the pharmacotherapy of obesity. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK279143/
Mittapalli, G.K., Roberts, E. (2014). Ligands of the neuropeptide Y Y2 receptor. Bioorg. Med. Chem. Lett., 24, 430-441.
